Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Dermatomyositis skin signs

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Bulbar, respiratory or rapidly progressive lung disease

Dysphagia, aspiration, weak cough, orthopnoea, falling respiratory strength, hypoxia or rapidly worsening breathlessness can reflect bulbar myositis, respiratory-muscle failure or aggressive interstitial lung disease.

Action: Admit for swallowing, gas exchange, seated and supine respiratory testing and urgent rheumatology, respiratory and critical-care input; restrict unsafe oral intake and treat infection and immune disease in parallel.

Synopsis

Recognise dermatomyositis across skin tones, detect clinically amyopathic and organ-threatening phenotypes, direct muscle, lung and malignancy assessment, and prevent scarring, calcinosis and treatment harm.

  • Gottron papules are violaceous or erythematous papules over knuckles; Gottron sign is flat change over extensor joints. Heliotrope eyelid colour and oedema are also characteristic.
  • Photosensitive shawl, V-neck and lateral-thigh holster eruptions, scalp inflammation, ragged cuticles and abnormal nailfold capillaries add a coherent skin phenotype.
  • In brown or black skin, inflammation may look purple-brown, grey or hyperpigmented and scale or oedema may be more visible than red colour.
  • Ask about stairs, rising from a chair, lifting arms, hair washing, swallowing, voice, cough and breathlessness and test objective proximal power rather than equating pain or fatigue with weakness.
  • Normal creatine kinase does not exclude dermatomyositis, clinically amyopathic disease or interstitial lung disease; use aldolase, other muscle enzymes, antibodies, MRI, EMG and tissue according to phenotype.
  • Anti-MDA5 with ulceration or palmar papules increases concern for rapidly progressive ILD, while anti-TIF1-gamma in adult-onset disease heightens malignancy vigilance.
  • Complete routine national cancer screening and add symptom-, age-, sex- and antibody-informed investigation near adult disease onset rather than applying one scan to everyone forever.
  • First-line skin care combines high-UVA photoprotection with a site-appropriate topical corticosteroid or calcineurin inhibitor; persistent or scarring disease needs systemic control.
  • Methotrexate, hydroxychloroquine, mycophenolate and other steroid-sparing medicines are selected by muscle, skin, lung and reproductive phenotype; methotrexate is once weekly, never daily.

Key red flags

Skin ulceration, palmar papules, anti-MDA5 phenotype, new dyspnoea, dysphagia, objective proximal weakness, myocarditis symptoms, constitutional decline or malignancy warning features requires expedited multidisciplinary assessment even when creatine kinase is normal.

Ulcerative MDA5 pattern

Painful ulcers over Gottron sites or nailfolds and palmar papules raise rapidly progressive ILD concern even without weakness.

Investigation priorities

01
Functional and manual muscle assessmentFirst step

Prove weakness, map distribution and establish an outcome baseline.

Management branches

First diagnostic sequenceUse skin to trigger whole-organ mapping

Gottron, heliotrope, photodistributed or nailfold features suggest dermatomyositis.

  1. Photograph skin in neutral light with consent and examine scalp, eyelids, knuckles, nails, hands and thighs, then measure proximal, neck and respiratory function and ask about swallow.
  2. Request muscle enzymes, renal and urine tests and phenotype-directed antibodies, adding skin biopsy, muscle MRI, EMG or muscle biopsy when the diagnosis remains uncertain.
  3. Screen lungs, swallowing, heart and malignancy from symptoms, disease onset and antibody risk and refer urgently for ulcerative MDA5 features or physiological compromise.
First-line skin treatmentProtect from light and suppress local activity

Cutaneous disease is limited and no organ-threatening feature requires immediate systemic rescue.

  1. Use high-UVA broad-spectrum sunscreen, shade and protective clothing and review photosensitising products while protecting vitamin D and quality of life.
  2. Apply a site-appropriate topical corticosteroid to active trunk, scalp or limb disease and use an off-label calcineurin inhibitor where face or folds make steroid atrophy unacceptable.

Key medicines

Site-appropriate topical corticosteroidApply a thin layer once daily to active nonfacial skin or scalp for a defined two-to-four-week course, then review before reducing or continuing intermittently.Use lower potency on eyelids, face and folds and monitor atrophy, telangiectasia, infection and total area; topical control cannot replace lung, muscle, swallow and malignancy assessment.
Hydroxychloroquine for skin-predominant diseaseTake 200–400 mg by mouth once daily with food without exceeding 5 mg/kg actual body weight daily, under specialist response and retinal review.Response is variable and dermatomyositis patients can develop drug eruptions. Review retinal, renal, cardiac, QT, glucose and interaction risk and stop and reassess a new widespread rash.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Association of Dermatologists dermatomyositisInclusive skin features, muscle and organ assessment and treatment.
  • BSR 2022 idiopathic inflammatory myopathy guidelineUK diagnosis, skin, muscle, lung, swallow, cancer and treatment recommendations.
  • NHS myositisAccessible recognition, investigations, rehabilitation and systemic treatment.
  • MHRA once-weekly methotrexate safetyCurrent UK safeguards against fatal daily-dose errors.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Review itch, scale, ulceration, poikiloderma and functional hand disease within weeks and escalate persistent or scarring activity rather than renewing topical treatment indefinitely.